These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 30239930)

  • 1. Multiple treatment comparison in narcolepsy: a network meta-analysis.
    Lehert P; Falissard B
    Sleep; 2018 Dec; 41(12):. PubMed ID: 30239930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating pitolisant as a narcolepsy treatment option.
    de Biase S; Pellitteri G; Gigli GL; Valente M
    Expert Opin Pharmacother; 2021 Feb; 22(2):155-162. PubMed ID: 32941089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J; Swick T; Bogan R; Lai C; Carter LP
    Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach.
    Lehert P; Szoeke C
    Drugs Context; 2020; 9():. PubMed ID: 32699548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
    Black J; Houghton WC
    Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFNS guidelines on management of narcolepsy.
    Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
    Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.
    Alshaikh MK; Tricco AC; Tashkandi M; Mamdani M; Straus SE; BaHammam AS
    J Clin Sleep Med; 2012 Aug; 8(4):451-8. PubMed ID: 22893778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
    Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
    Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
    Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of narcolepsy and other hypersomnias of central origin.
    Wise MS; Arand DL; Auger RR; Brooks SN; Watson NF;
    Sleep; 2007 Dec; 30(12):1712-27. PubMed ID: 18246981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis.
    Chien PY; Kuo CY; Lin MH; Chang YJ; Hung CC
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study.
    Dauvilliers Y; Arnulf I; Szakacs Z; Leu-Semenescu S; Lecomte I; Scart-Gres C; Lecomte JM; Schwartz JC;
    Sleep; 2019 Oct; 42(11):. PubMed ID: 31529094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of narcolepsy with and without cataplexy.
    Kallweit U; Bassetti CL
    Expert Opin Pharmacother; 2017 Jun; 18(8):809-817. PubMed ID: 28443381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
    Lamb YN
    CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
    Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.